These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38532484)

  • 1. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.
    Alonso Ruiz A; Bezruki A; Shinabargar E; Large K; Vieira M; Slovenski I; Liu Y; Agarwal S; Becker A; Moon S
    Global Health; 2024 Mar; 20(1):25. PubMed ID: 38532484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally.
    ShamaeiZadeh PA; Jaimes CV; Knoll MD; Espié E; Chandler RE
    Vaccine X; 2024 Jun; 18():100485. PubMed ID: 38655548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global survey in the developmental landscape of possible vaccination strategies for COVID-19.
    Gasmi A; Srinath S; Dadar M; Pivina L; Menzel A; Benahmed AG; Chirumbolo S; Bjørklund G
    Clin Immunol; 2022 Apr; 237():108958. PubMed ID: 35218966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global support for new vaccine implementation in middle-income countries.
    Kaddar M; Schmitt S; Makinen M; Milstien J
    Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
    Borges LC; Zeferino de Menezes H; Crosbie E
    Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operation Warp Speed: implications for global vaccine security.
    Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members
    Lancet Glob Health; 2021 Jul; 9(7):e1017-e1021. PubMed ID: 33780663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How manufacturing won or lost the COVID-19 vaccine race.
    King ML
    Vaccine; 2024 Feb; 42(5):1004-1012. PubMed ID: 38228438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Race for Global Equitable Access to COVID-19 Vaccines.
    Md Khairi LNH; Fahrni ML; Lazzarino AI
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequity in access to vaccines: the failure of the global response to the COVID-19 pandemic.
    Ugalde A; Hellmann F; Homedes N
    Salud Colect; 2022 Oct; 18():e4190. PubMed ID: 36520487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of geo-political socio-economic factors on vaccine dissemination trends: a case-study on COVID-19 vaccination strategies.
    Chauhan R; Varma G; Yafi E; Zuhairi MF
    BMC Public Health; 2023 Nov; 23(1):2142. PubMed ID: 37919737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
    Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
    Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
    Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
    Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.
    Chung YH; Beiss V; Fiering SN; Steinmetz NF
    ACS Nano; 2020 Oct; 14(10):12522-12537. PubMed ID: 33034449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.